{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:41:27Z","timestamp":1793256087285,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13555-024-01327-5","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:18:07Z","timestamp":1737548287000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-920X","authenticated-orcid":false,"given":"Annika","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidin","family":"Karahasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Yapabandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Elhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735\u201341. https:\/\/doi.org\/10.1001\/jama.296.14.1735.","journal-title":"JAMA"},{"key":"1327_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","volume":"159","author":"JA Kaye","year":"2008","unstructured":"Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895\u2013902. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08707.x.","journal-title":"Br J Dermatol"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2017.03.037","volume":"77","author":"K Shah","year":"2017","unstructured":"Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77:287\u201392. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.037.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1327_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00403-013-1437-3","volume":"306","author":"L Ma","year":"2014","unstructured":"Ma L, Li M, Wang H, Li Y, Bai B. High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China. Arch Dermatol Res. 2014;306(3):247\u201351. https:\/\/doi.org\/10.1007\/s00403-013-1437-3.","journal-title":"Arch Dermatol Res"},{"key":"1327_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1529-8019.2010.01304.x","volume":"23","author":"L Naldi","year":"2010","unstructured":"Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010;23:114\u20138. https:\/\/doi.org\/10.1111\/j.1529-8019.2010.01304.x.","journal-title":"Dermatol Ther"},{"key":"1327_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","volume":"78","author":"MT Wan","year":"2018","unstructured":"Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78:315\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.050.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1327_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"25","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;25(11):117. https:\/\/doi.org\/10.3389\/fphar.2020.00117.","journal-title":"Front Pharmacol"},{"issue":"3 Pt 1","key":"1327_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","volume":"132","author":"SM Langan","year":"2012","unstructured":"Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556\u201362.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1327_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2340\/00015555-0510","volume":"88","author":"J Dreiher","year":"2008","unstructured":"Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008;88(6):561\u20135. https:\/\/doi.org\/10.2340\/00015555-0510.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1327_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"5","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;5(9):579. https:\/\/doi.org\/10.3389\/fimmu.2018.00579.","journal-title":"Front Immunol"},{"issue":"8","key":"1327_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695\u2013706. https:\/\/doi.org\/10.1111\/jdv.16273.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1327_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S159163","volume":"17","author":"JG Holm","year":"2019","unstructured":"Holm JG, Thomsen SF. Type\u00a02 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019;17(9):1\u20136. https:\/\/doi.org\/10.2147\/PTT.S159163.","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"1327_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/ijd.14349","volume":"58","author":"L Chularojanamontri","year":"2019","unstructured":"Chularojanamontri L, Silpa-Archa N, Wongpraparut C, Limphoka P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int J Dermatol. 2019;58(5):593\u20139. https:\/\/doi.org\/10.1111\/ijd.14349.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1327_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/jama.1989.03430010065032","volume":"262","author":"CM Ballantyne","year":"1989","unstructured":"Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989;262(1):53\u20136. https:\/\/doi.org\/10.1001\/jama.1989.03430010065032.","journal-title":"JAMA"},{"issue":"4","key":"1327_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvz009.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"1327_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","volume":"4","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885\u201391. https:\/\/doi.org\/10.1001\/jamacardio.2019.2589.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1327_CR17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","volume":"147","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study. Arch Dermatol. 2011;147(9):1031\u20139. https:\/\/doi.org\/10.1001\/archdermatol.2011.119.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1327_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, et al. A phase\u00a0IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140(1):85-93.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.07.679.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1327_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784-1793.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.01.025.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1327_CR20","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","volume":"141","author":"A Gonz\u00e1lez-Cantero","year":"2021","unstructured":"Gonz\u00e1lez-Cantero A, Ortega-Quijano D, \u00c1lvarez-D\u00edaz N, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. J Invest Dermatol. 2021;141(10):2402\u201311.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1327_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4239\/wjd.v12.i3.238","volume":"12","author":"CR Wang","year":"2021","unstructured":"Wang CR, Tsai HW. Anti- and non-tumor necrosis factor-\u03b1-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. World J Diabetes. 2021;12(3):238\u201360. https:\/\/doi.org\/10.4239\/wjd.v12.i3.238.","journal-title":"World J Diabetes"},{"issue":"1\u20132","key":"1327_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cca.2005.08.010","volume":"365","author":"Y Allanore","year":"2006","unstructured":"Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta. 2006;365(1\u20132):143\u20138. https:\/\/doi.org\/10.1016\/j.cca.2005.08.010.","journal-title":"Clin Chim Acta"},{"key":"1327_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1196\/annals.1351.039","volume":"1069","author":"B Seriolo","year":"2006","unstructured":"Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-\u03b1 treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:414\u20139. https:\/\/doi.org\/10.1196\/annals.1351.039.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1327_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/ard.2004.023119","volume":"64","author":"C Popa","year":"2005","unstructured":"Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):303\u20135. https:\/\/doi.org\/10.1136\/ard.2004.023119.","journal-title":"Ann Rheum Dis"},{"issue":"23\u201324","key":"1327_CR25","first-page":"1004","volume":"114","author":"E Cauza","year":"2002","unstructured":"Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr. 2002;114(23\u201324):1004\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"1327_CR26","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/ard.2006.059691","volume":"66","author":"MJ Peters","year":"2007","unstructured":"Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):958\u201361. https:\/\/doi.org\/10.1136\/ard.2006.059691.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1327_CR27","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10067-007-0539-8","volume":"26","author":"LS Tam","year":"2007","unstructured":"Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1495\u20138. https:\/\/doi.org\/10.1007\/s10067-007-0539-8.","journal-title":"Clin Rheumatol"},{"key":"1327_CR28","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fimmu.2018.01234","volume":"9","author":"AP Sajja","year":"2018","unstructured":"Sajja AP, Joshi AA, Teague HL, Dey AK, Mehta NN. potential immunological links between psoriasis and cardiovascular disease. Front Immunol. 2018;9:1234. https:\/\/doi.org\/10.3389\/fimmu.2018.01234.","journal-title":"Front Immunol"},{"issue":"1","key":"1327_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","volume":"67","author":"Kimball","year":"2012","unstructured":"Kimball, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.035.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1327_CR30","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784-1793.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.01.025.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1327_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jdv.16004","volume":"34","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533\u201341. https:\/\/doi.org\/10.1111\/jdv.16004.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1327_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","volume":"9","author":"JF Merola","year":"2022","unstructured":"Merola JF, McInnes IB, Deodhar AA, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u201355. https:\/\/doi.org\/10.1007\/s40744-022-00434-z.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"1327_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/life11060535","volume":"11","author":"\u00c9A Piros","year":"2021","unstructured":"Piros \u00c9A, Szab\u00f3 \u00c1, Rencz F, et al. Anti-Interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters\u2019 levels, but has no effect on body composition parameters. Life (Basel). 2021;11(6):535. https:\/\/doi.org\/10.3390\/life11060535.","journal-title":"Life (Basel)"},{"issue":"6","key":"1327_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1684\/ejd.2011.1548","volume":"21","author":"S Lestre","year":"2011","unstructured":"Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol. 2011;21(6):916\u201320. https:\/\/doi.org\/10.1684\/ejd.2011.1548.","journal-title":"Eur J Dermatol"},{"key":"1327_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13075-016-1148-1","volume":"18","author":"S Hassan","year":"2016","unstructured":"Hassan S, Milman U, Feld J, et al. Effects of anti-TNF-\u03b1 treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther. 2016;18:261. https:\/\/doi.org\/10.1186\/s13075-016-1148-1.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1327_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fphar.2020.00481","volume":"15","author":"O Patsalos","year":"2020","unstructured":"Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-\u03b1 inhibitors on body weight and bmi: a systematic review and meta-analysis. Front Pharmacol. 2020;15(11):481. https:\/\/doi.org\/10.3389\/fphar.2020.00481.","journal-title":"Front Pharmacol"},{"issue":"Suppl D","key":"1327_CR37","doi-asserted-by":"publisher","first-page":"7D","DOI":"10.1016\/s0828-282x(08)71043-2","volume":"24","author":"JP Despr\u00e9s","year":"2008","unstructured":"Despr\u00e9s JP, Arsenault BJ, C\u00f4t\u00e9 M, Cartier A, Lemieux I. Abdominal obesity: the cholesterol of the 21st century? Can J Cardiol. 2008;24(Suppl D):7D-12D. https:\/\/doi.org\/10.1016\/s0828-282x(08)71043-2.","journal-title":"Can J Cardiol"},{"issue":"10","key":"1327_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325. https:\/\/doi.org\/10.1007\/s40261-021-01080-z.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1327_CR39","doi-asserted-by":"publisher","first-page":"9289","DOI":"10.1038\/s41598-021-88552-6","volume":"11","author":"I Olejniczak-Staruch","year":"2021","unstructured":"Olejniczak-Staruch I, Narbutt J, Ceryn J, et al. Kraska-Gacka M, Ci\u0105\u017cy\u0144ska M, \u015amigielski J, et al. AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings. Sci Rep. 2021;11(1):9289. https:\/\/doi.org\/10.1038\/s41598-021-88552-6.","journal-title":"Sci Rep"},{"issue":"8","key":"1327_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.36849\/JDD.2020.5337","volume":"19","author":"MA Menter","year":"2020","unstructured":"Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase\u00a03 trials (ReSURFACE 1 and ReSURFACE 2). J Drugs Dermatol. 2020;19(8):703\u20138. https:\/\/doi.org\/10.36849\/JDD.2020.5337.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01327-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01327-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01327-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:31:35Z","timestamp":1738362695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01327-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01327-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared. Sarah Zaman has received unrestricted research grants to their institution from Abbott and Biotronik as well as consulting fees and speaking honoraria from Novartis, The Limbic, Medtronic, AstraZeneca, the Heart Foundation and Boehringer Ingelheim, that is unrelated to the content of this manuscript. Dr Annika Smith has received institutional support and\/or consulting fees and\/or speaking honoraria from UCB, AbbVie, Eli Lilly, Janssen, Amgen, BMS, Novartis, Sun pharma, GSK, LEO pharma, that is unrelated to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Ethics Committee at Westmead Hospital, NSW, Australia (reference number 2201-06) and was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}